Wilson Sonsini - ECP

insight detail

Wilson Sonsini Advises Kedalion on Series B Funding, Signing of Option to Acquire Agreement

  • 11/16/21
  • Client Highlights
  • Life Sciences
  • Biotech

On November 15, 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an exclusive option to acquire the company and its AcuStream technology. The agreement follows a feasibility study agreement with the AcuStream technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the two parties is ongoing. The financial and other terms of this transaction have not been disclosed.

Wilson Sonsini Goodrich & Rosati represented Kedalion on both transactions. The team included:

Corporate/M&A
Ken Clark
Michael Coke
Ethan Lutske
Kenji Strait
Mary Chamaki
Stephanie C. Chen

IP/Technology Transactions 
Lowell Segal
Norman Hovijitra
Miruna Predescu
Tony Nguyen

Tax
Myra Sutanto Shen

Employment
Rebecca Stuart
Briza Sanchez
Andrew Velazquez

Employee Benefits and Compensation
Scott McCall
Michael Klippert
Jason Chan

FDA/Regulatory
David Hoffmeister
Eva Yin

For more information, please see Kedalion's press release.

ECP Attorneys:

Copyright © 2022 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.